Destiny Pharma Plc

Destiny Pharma Plc DEST

Dividend Summary



There have not been any declared dividends recently.

Latest Dividends
Summary Previous dividend Next dividend
Status
Type
Per share
Declaration date
Ex-div date
Pay date

Enter the number of Destiny Pharma Plc shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
We have not made any dividend predictions for Destiny Pharma Plc
Dividend Yield Today
0.0%
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for Destiny Pharma Plc
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
There are no Destiny Pharma Plc dividends.
Year Amount Change
2006 0.0p
2007 0.0p
0%
2008 0.0p
0%
2009 0.0p
0%
2010 0.0p
0%
2011 0.0p
0%
2012 0.0p
0%
2013 0.0p
0%
2014 0.0p
0%
2015 0.0p
0%
2016 0.0p
0%
2017 0.0p
0%
2018 0.0p
0%
2019 0.0p
0%
2020 0.0p
0%
2021 0.0p
0%
2022 Sign Up Required

Destiny Pharma Plc Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
0.0%
Optimized Yield
Sign Up Required
52 Week High
0.0% on 04 May 2022
52 Week Low
0.0% on 04 May 2022
Next Ex-Div-Date Countdown
Sign Up Required

About Destiny Pharma Plc

 

Destiny Pharma plc is a clinical stage, biotechnology company. The Company is engaged in the discovery, development, and commercialization of novel medicines with a focus on infection prevention. It is focused on developing novel antimicrobial drug from its exeporfinium chloride platform and also from two biotherapeutic products. Its pipeline includes XF-73 nasal gel, NTCD-M3, and XF-73 dermal. XF-73 nasal gel is developed for the prevention of post-surgical staphylococcal infections. NTCD-M3, which is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins. NTCD-M3 is used for the prevention of C. difficile infection (CDI) recurrence. XF-73 derma is developed for the prevention and treatment of serious infections associated with wounds and ulcers such as diabetic foot ulcers (DFUs). The Company is co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections.

Sector
Pharmaceuticals & Biotechnology
Country
United Kingdom
Share Price
£0.46 (yesterday's closing price)
Shares in Issue
73 million
Market Cap
£33mn
CADI
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
0
Market Indices
none
No articles found